Novo Nordisk will cut insulin prices in the United States. The Danish drug makers will offer more economical insulin to U.S. diabetics after they and peers’ Lilly and Sanofi were heavily criticized for steep pricing that was putting those diabetics in lower socioeconomic strata at severe health risk.
Novo Nordisk will offer a generic version of its most heavily prescribed insulin drug Novolog used by about one million patients in America reports Reuters.
Novo Nordisk’s competitors had already initiated price cuts so it was the Danes turn. The cost of insulin for treating type 1 diabetes nearly doubled over five years—leading to rationing the medication in some cases. Really not what one would think would happen in America in 2019—rationing.